Home >> Endocrinology/Metabolics >> Endocrinology/Metabolics >> Baked Goods >> Technology & Media >>

Post Menopausal Osteoporosis - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 86 | Code: MRS - 18271

Post Menopausal Osteoporosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Pipeline Review, H1 2015’, provides an overview of the Post Menopausal Osteoporosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Post Menopausal Osteoporosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Post Menopausal Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post Menopausal Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Post Menopausal Osteoporosis Overview 8
Therapeutics Development 9
Pipeline Products for Post Menopausal Osteoporosis - Overview 9
Pipeline Products for Post Menopausal Osteoporosis - Comparative Analysis 10
Post Menopausal Osteoporosis - Therapeutics under Development by Companies 11
Post Menopausal Osteoporosis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Post Menopausal Osteoporosis - Products under Development by Companies 15
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development 16
Amgen Inc. 16
Chronos Therapeutics Limited 17
Eli Lilly and Company 18
Hanmi Pharmaceuticals, Co. Ltd. 19
Merck & Co., Inc. 20
Oncobiologics, Inc. 21
Paras Biopharmaceuticals Finland Oy 22
Pfizer Inc. 23
Radius Health, Inc. 24
Unigene Laboratories, Inc. 25
Post Menopausal Osteoporosis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(aceclofenac + eperisone) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
abaloparatide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
bazedoxifene acetate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
blosozumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
calcitonin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
denosumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
denosumab biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Drugs for Postmenopausal Osteoporosis - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
odanacatib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
RDC-5 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
romosozumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
teriparatide biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Post Menopausal Osteoporosis - Recent Pipeline Updates 56
Post Menopausal Osteoporosis - Dormant Projects 70
Post Menopausal Osteoporosis - Discontinued Products 71
Post Menopausal Osteoporosis - Product Development Milestones 72
Featured News & Press Releases 72
Jan 29, 2015: Radius Health Announces Oral Presentation of the ACTIVE Phase 3 Clinical Trial of Abaloparatide-SC for Postmenopausal Women With Osteoporosis at ICE/ENDO 2015 72
Dec 21, 2014: Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis 73
Nov 24, 2014: The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase II Study of the Investigational Drug Abaloparatide in Postmenopausal Women With Osteoporosis 74
Sep 15, 2014: Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia (Denosumab) In Postmenopausal Women With Osteoporosis 75
Sep 15, 2014: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis 77
Sep 15, 2014: New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 79
Aug 13, 2014: Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director 81
Jan 09, 2014: Radius Announces Positive Topline Data From Phase 2 Study of Abaloparatide (BA058) for Postmenopausal Osteoporosis Using Two Delivery Systems 81
Jan 02, 2014: Romosozumab phase 2 data published in New England Journal of Medicine show significant increases in bone mineral density at both spine and hip 83
Dec 31, 2013: Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, H1 2015 9
Number of Products under Development for Post Menopausal Osteoporosis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H1 2015 16
Post Menopausal Osteoporosis - Pipeline by Chronos Therapeutics Limited, H1 2015 17
Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H1 2015 18
Post Menopausal Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 19
Post Menopausal Osteoporosis - Pipeline by Merck & Co., Inc., H1 2015 20
Post Menopausal Osteoporosis - Pipeline by Oncobiologics, Inc., H1 2015 21
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015 22
Post Menopausal Osteoporosis - Pipeline by Pfizer Inc., H1 2015 23
Post Menopausal Osteoporosis - Pipeline by Radius Health, Inc., H1 2015 24
Post Menopausal Osteoporosis - Pipeline by Unigene Laboratories, Inc., H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Assessment by Combination Products, H1 2015 27
Number of Products by Stage and Target, H1 2015 29
Number of Products by Stage and Mechanism of Action, H1 2015 31
Number of Products by Stage and Route of Administration, H1 2015 33
Number of Products by Stage and Molecule Type, H1 2015 35
Post Menopausal Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2015 56
Post Menopausal Osteoporosis - Dormant Projects, H1 2015 70
Post Menopausal Osteoporosis - Discontinued Products, H1 2015 71

List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, H1 2015 9
Number of Products under Development for Post Menopausal Osteoporosis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Top 10 Targets, H1 2015 28
Number of Products by Stage and Top 10 Targets, H1 2015 29
Number of Products by Top 10 Mechanism of Actions, H1 2015 30
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 31
Number of Products by Top 10 Routes of Administration, H1 2015 32
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 33
Number of Products by Top 10 Molecule Types, H1 2015 34
Number of Products by Stage and Top 10 Molecule Types, H1 2015 35

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing